Home
HelpTest Code PIFXSO Anser IFX, Prometheus (Infliximab/Remicade) (3150)
Additional Codes
Prometheus Test Code: 3150
Useful For
To measure and monitor serum infliximab (IFX) and antibodies-to-infliximab (ATI) levels at any time during therapy.
Synonyms/Keywords
Test is NOT available for Outreach clients (but is available to MMC-Dickinson).
Specimen Requirements
| Fasting Required | Specimen Type | Preferred Container/Tube | Acceptable Container/Tube | Specimen Volume | Specimen Minimum Volume (allows for 1 repeat) |
Pediatric Minimum Volume (no repeat) |
|---|---|---|---|---|---|---|
| Serum | Serum Separator Tube (SST) | Red Top Tube (RTT) | 2.0 mL |
Collection/Processing Instructions
Send ambient or cold pack. Do not freeze.
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Ambient | 14 days |
| Refrigerated | 14 days |
Rejection Criteria
Frozen specimens, Whole blood
Test Information
This test was developed and its performance characteristics determined by Prometheus Laboratories, CAP-accredited (6805501) and CLIA-certified (05D0917432) as qualified to perform high complexity testing. It has not been cleared or approved by the US Food and Drug Administration
The Anser IFX test is a quantitative therapeutic drug monitoring (TDM) assay that allows healthcare providers to measure and monitor serum infliximab (IFX) and antibodies-to-infliximab (ATI) levels at any time during therapy.
Serum concentrations of infliximab (IFX) may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of IFX have been linked to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to IFX by producing ATI. The presence of ATI has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of IFX and ATI levels in serum provides valuable information to healthcare providers to better assess a patient's risk or reason for losing response to IFX and helps them decide an appropriate course of action.
Serum infliximab (IFX) Lower Limit of Quantification: < 1.0 ug/mL
Antibody to infliximab (ATI) Lower Limit of Quantification: < 3.1 U/mL
Performing Laboratory Name
Prometheus Labs
Referral Laboratory Information
| Address | Telephone | Website Link | Marshfield Lab Account # |
|---|---|---|---|
| 9410 Carroll Park Dr. San Diego, CA 92121 |
888-423-5227 | https://prometheuslabs.com/ | 1299 |
Performing Information
| Performing Location | Day(s) Test Performed | Analytical Time | Methodology/Instrumentation |
|---|---|---|---|
| Prometheus Laboratories |
|
3 days |
CPT Codes
| CPT | Modifier (if needed) |
Quantity | Description | Comments |
|---|---|---|---|---|
| 80230 | 1 | Serum infliximab (IFX) concentration | ||
| 82542 | 1 | Antibody to infliximab (ATI) concentration |
Ordering Applications
| Ordering Application | Description |
|---|---|
| Cerner | Anser IFX, Prometheus (Infliximab/Remicade) (3150) |